Molecular Variants in Disease

Symposium organized by The Royal College of Pathologists delivered in London in February 1974

Edited by D. N. RAINE

Published for The Royal College of Pathologists by the Journal of Clinical Pathology, BMA House, Tavistock Square London WC1H 9JR England COPYRIGHT © 1974 by The Royal College of Pathologists

Index

Alleliam, multiple, at different loci, isozymes due to, 125 —, at single locus, 32 Amniocratesis, 150 Chondroitid Asulphaturia, 73 Chondroitid Asulphaturia, 74 Charto		
Amniocit faid as medium for antenatal diagnosis, 151 — cell culture, 150 AMP; pyrophosphate phosphoribosyltransferase deficiency, 57 Anti-sickling drug, 24 Apoenzymes, specific, defective binding of vitamin coenzymes to, 40 BELLINGHAM, J.: The sickling process in relation to clinical manifestations, 23 Branching enzyme deficiency, 115 BROCK, D. J. H.: Prenatal diagnosis and genetic counselling, 150 Chondrotina Asulphaturia, 74 CLAYTON, B. E.: Population screening, 145 COMMUNITY, problems affecting, 145-163 COMMUNITY, problems affecting, 145-163 Community, problems affecting, 145-163 — in erythrocytes, 121-144 — in sphingolipidoses, 96 — mutants, increased steady-state concentration with slight residual activity, strip in hemotic of sample in creases in, 43 Erythrocytes, 128-144 — oxygen affinity changes in, physiological consequences of, 142 — precursors, protein and nucleic acid synthesis in, general pattern of, 2 — precursors, protein and nucleic acid synthesis in, general pattern of, 2 — precursors, protein and nucleic acid synthesis in, general pattern of, 2 — chemistry of, 81 — production, control during maturation, 9 — the synthesis, 6 — disease, 64 — in sphingolipidoses, 96 — mutants, increased steady-state concentration with slight residual activity, strip in, benefit of small increases in, 43 Erythrocytes, 128-144 — oxygen affinity changes in, physiological consequences of, 142 — precursors, protein and nucleic acid synthesis in, general pattern of, 2 — precursors, protein and nucleic acid synthesis in, general pattern of, 2 — precursors, protein and nucleic acid synthesis in, general pattern of, 2 — precursors, protein and nucleic acid synthesis in, general pattern of, 2 — precursors, protein and nucleic acid synthesis in, general pattern of, 2 — precursors, protein and nucleic acid synthesis in, general pattern of, 2 — precursors, protein and nucleic acid synthesis in, general pattern of, 2 — precursors, protein and nucleic acid synthesis in general pattern of, 2 — precursors, protein and nucleic aci	Allelism, multiple, at different loci, isozymes due to, 125	diseases, 106
Amniocentesis, 150 Amniotic field as medium for antenatal diagnosis, 151 Amniotic field as medium for antenatal diagnosis, 150 Amniotic field as medium for antenatal diagnosis, 150 Amniotic field as medium for antenatal diagnosis of tamin coenzymes to, 40 BELLINGHAM, A. J.: The sickling process in relation to clinical manifestations of the process of the pro	,, at multiple loci, 34	, unclassified, 117
Administration deforms of antenstal diagnosis, 151 ——————————————————————————————————	, at single locus, 32	
Amnotic fluid as medium for antenatal diagnosis, 151 — cell culture, 150 AMP; pyrophosphate phosphoribosyltransferase deficiency, 57 Anti-sicking drugs, 24 Apoensymes, specific, effective binding of vitamin coenzymes to, 40 Apoensymes, specific, effective binding of vitamin coenzymes to, 40 Apoensymes, specific, effective binding of vitamin coenzymes to, 40 Apoensymes, specific, effective binding of vitamin coenzymes to, 40 Apoensymes, specific, effective binding of vitamin coenzymes to, 40 Apoensymes, specific, effective binding of vitamin coenzymes to, 40 Apoensymes, specific, effective binding of vitamin coenzymes to, 40 Apoensymes, specific, effective binding of vitamin coenzymes to, 40 Apoensymes, specific, effective binding of vitamin coenzymes to, 40 Chondrolind -sulphaturia, 73 Chondrolind -sulphaturia, 73 Chondrolind -sulphaturia, 73 Chondrolind -sulphaturia, 74 CATYON, B. E. Population screening, 145 Community, problems affecting, 145-163 Cysine fibrosis, scereaing for, 149 Debranching enzyme deficiency, 114 Expression enzyme sefficiency, 115 Expression enzyme sefficiency, 114 Expressions, protein and nucleic acid synthesis in, general pattern of, 22 Expressions, protein and nucleic acid synthesis in, general pattern of, 22 Expressions, protein and nucleic acid synthesis in, general pattern of, 22 Expressions, protein and nucleic acid synthesis in, general pattern of, 22 Expressions, protein and nucleic acid synthesis in, general pattern of, 22 Expressions, protein and nucleic acid synthesis in, general pattern of, 22 Expressions, protein and nucleic acid synthesis in, general pattern of, 22 Expressions, protein and nucleic acid synthesis in, general pattern	Amniocentesis 150	
MAP: proprobaphate phosphoribosyltransferase deficiency, 57 Anti-sickling drugs, 24 Apoenzymes, specific, defective binding of vitamin coenzymes to, 40 BRLLNOHAM, A. 1.: The sickling process in relation to clinical manifestations, 23 Branching enzyme deficiency, 113 BRANCHA, D. 1.: Prenatal diagnosis and genetic counselling, 159 Chondrotiin 4-sulphaturia, 73 CLAYTON, B. E.: Population screening, 145 COmmunity, problems affecting, 145-163 Cystic fibrosis, screening for, 148 Debranching enzyme deficiency, 111 Enzyme deficiencis, different degrees of, in sphingolipidoses, 100 — in erythrocytes, 128-144 Enzyme complex and the sulphaturia, 73 Cystic fibrosis, screening for, 148 Enzyme deficiencis, different degrees of, in sphingolipidoses, 100 — in erythrocytes, 128-144 Enzyme deficiency, 112 Enzyme deficiency, 114 Enzyme deficiency, 117 Enzyme deficiency, 114 Enzyme deficiency, 117 Enzyme deficiency, 114 Enzyme deficiency, 116 Enzyme deficiency, 117 Enzyme deficiency, 117 Enzyme deficiency, 118 Enzyme deficiency, 119 Enzyme, 120 Enz		Gout, 55
AMP: pyrophosphate phosphoribosyltransferase deficiency, 57 Antiscking drug, 24 Apoenzymes, specific, defective binding of vitamin coenzymes to, 40 SELLINGHAM, A. 1: The sickling process in relation to clinical manifestations, 23 Branching enzyme deficiency, 115 BROCK, D. J. Ht.: Prenatal diagnosis and genetic counselling, 150 Chondroitin 6-sulphaturia, 73 Chondro	——————————————————————————————————————	Haem synthesis, 6
Anti-sickling drugs, 24 Aporenzymes, specific, defective binding of vitamin coenzymes to, 40 BELLINGHAM, A. J.: The sickling process in relation to clinical manifestatus of 19 BELLINGHAM, A. J.: The sickling process in relation to clinical manifestatus of 19 BELLINGHAM, A. J.: The sickling process in relation to clinical manifestatus of 19 BELLINGHAM, A. J.: The sickling process in relation to clinical manifestatus of 19 BELLINGHAM, A. J.: The sickling process in relation to clinical manifestatus of 19 BELLINGHAM, A. J.: The sickling process in relation to clinical manifestatus of 19 BELLINGHAM, A. J.: The sickling process in relation to clinical manifestatus of 19 BELLINGHAM, A. J.: The sickling process in relation to clinical manifestatus of 19 BELLINGHAM, A. J.: The sickling process in relation to clinical manifestatus of 19 BELLINGHAM, A. J.: The sickling process in relation to clinical manifestatus of 19 BELLINGHAM, A. J.: The sickling process in relation to clinical manifestatus of 19 BELLINGHAM, A. J.: The sickling process in relation to clinical manifestatus of 19 BELLINGHAM, A. J.: The sickling process in relation to clinical manifestatus of 19 BELLINGHAM, A. J.: The sickling process in relation to clinical manifestatus of 6, 3 — minimity, problems affectines, 1145 Bellingham, S.: The sickling process in relation to clinical manifestaturs of 6, 6 — compositions of 2 — in exphroacial diagnosis and genetic counselling, 150 — in exphroacies, different degrees of, in sphingolipidoses, 10 Harmodolinopathies, 12-37 Harmodolin		
### Debranching and protections of the production, support of the production, support of the production, support of the production, control during matrition, 9 ### Community, problems affecting, 145-163 ### Debranching enzyme deficiency, 114 ### Enzyme deficiencies, different degrees of, in sphingolipidoses, 100 ### In erythrocytes, 128-144 ### Enzyme deficiencies, different degrees of, in sphingolipidoses, 100 ### In erythrocytes, 128-144 ### Enzyme deficiencies, 128-144 ### In a phingolipidoses, 96 ### In unitants, increased steady-state concentration with slight residual activity, 42 ### In unitants, increased steady-state concentration with slight residual activity, 42 ### In unitants, increased steady-state concentration with slight residual activity, 42 ### In unitants, increased steady-state concentration with slight residual activity, 42 ### In unitants, increased steady-state concentration with slight residual activity, 42 ### In unitants, increased steady-state concentration with slight residual activity, 42 ### In unitants, increased steady-state concentration with slight residual activity, 42 ### In unitants, increased steady-state concentration with slight residual activity, 42 ### In unitants, increased steady-state concentration with slight residual activity, 42 ### In unitants, increased steady-state concentration with slight residual activity, 42 ### In unitants, increased steady-state concentration with slight residual activity, 42 ### In unitants, increased steady-state concentration with slight residual activity, 42 ### In unitants, increased steady-state concentration with slight residual activity, 42 ### In unitants, increased steady-state concentration with slight residual activity, 42 ### In unitants, increased steady-state concentration with slight residual activity, 42 ### In unitants, increased steady-state concentration with slig		disease, unstable, approach to diagnosis in, 20
### Sell-Inchition A. J.: The sickling process in relation to clinical manifes actions, 23 arong the process of the process of the production, complexations of, 22 treatment of, 21 treatment of, 22 treatment of, 21 treatment of, 22 treatment of, 22 treatment of, 21 treatment of, 22 treatment of, 21 treatment of, 22 treatment of, 22 treatment of, 21 treatment of, 23 treatment of, 21 treatment of, 21 treatment of, 21 treatment of, 22 treatment of, 22 treatment of, 22 treatment of, 23 treatment of, 23 treatment of, 24 treatment of, 25 treatment o		,, clinical features of, 19
## Branching enzyme deficiency, 115 ## Broack, D. J. H.: Prenatal diagnosis and genetic counselling, 150 Chondroitin 4-sulphaturia, 74 CLAYTON, B. E.: Population screening, 145 Community, problems affecting, 145-163 Cystic fibrosis, screening for, 148 Debranching enzyme deficiency, 114 Enzyme deficiencies, different degrees of, in sphingolipidoses, 100 ———————————————————————————————————		,, presentation in, 19
## Branching enzyme deficiency, 115 ## Broack, D. J. H.: Prenatal diagnosis and genetic counselling, 150 Chondroitin 4-sulphaturia, 74 CLAYTON, B. E.: Population screening, 145 Community, problems affecting, 145-163 Cystic fibrosis, screening for, 148 Debranching enzyme deficiency, 114 Enzyme deficiencies, different degrees of, in sphingolipidoses, 100 ———————————————————————————————————		,, complications of, 22
SROCK, D. J. M.: Prenatal diagnosis and genetic counselling, 150 Chondroitin 4-sulphaturia, 73 Chondroitin 6-sulphaturia, 73 Chondroitin 6-sulphaturia, 73 Cystic fibrosis, screening for, 148 Enzyme deficiencies, different degrees of, in sphingolipidoses, 100 ——in erythrocytes, 128-144 Enzyme deficiencies, 118-1419 thanges in, physiological consequences of, 102 ——in sphingolipidoses, 96 ——un asphingolipidoses, 96 ——un asphingolipidoses, 96 ——un sphingolipidoses, 96 ——un sphingolipi		, treatment of, 21
Chondroitin 4-sulphaturia, 73 Chondroitin 6-sulphaturia, 74 Chondroitin 6-sulphaturia, 74 Community, problems affecting, 145-163 Debranching enzyme deficiency, 114 Enzyme deficiencies, different degrees of, in sphingolipidoses, 100 — in erythrocytes, 128-144 — oxygen affinity changes in, physiological consequences of, 142 — in sphingolipidoses, 96 — mutants, increased steady-state concentration with slight residual activity, 42 — oxygen affinity changes in, physiological consequences of, 142 — oxygen affinity changes in, physiological consequences of, 144 — oxygen affinity changes in, physiological consequences, 128-144 — oxygen affinity in the red cell enzyme defects, 142 — oxygen affinity changes in, physiological consequences of changes in oxygen affinity in the red cell enzyme defects, 142 — oxygen affinity changes in,		
Chondroitin 6-sulphaturia, 74 CLAYTON, 8. E.: Population screening, 145 Cystic fibrosis, screening for, 148 Debranching enzyme deficiency, 114 Enzyme deficiencies, different degrees of, in sphingolipidoses, 100 — in erythrocytes, 128-144 — o., oxygen affinity changes in, physiological consequences of, 142 — in sphingolipidoses, 96 — mutants, increased steady-state concentration with slight residual activity, 42 — low activity in, benefit of small increases in. 43 Erythrocyte enzyme deficiencis, 128-144 — oxygen affinity changes in, physiological consequences of, 142 — procursors, protein and nucleic acid synthesis in, physiological consequences, 142 — protein synthesis in, 5 — private kinase in, 128 Erythropoiesis, ineffective, in β-thalassaemia major, 13 Fucosidosis, 82 — chemistry of, 83 — pathological data in, 82 Galactosaemia, screening for, 147 Gyr, Gangliosidosis, 79 — chemistry of, 81 — in inherited disease, 32 Glucose-6-phosphatae dehydrogenase, defective molecular variants of, 134, 135 — deficiency, fluture prospects for study of, 136 — heterogeneity of, 134 β-Glucoroidosis deficiency, 74 Glutathione reductase activity, increase in, 54 Glycogen metabolism, disorders of, 108 — yathesis, regulation of, 6 — nextractional, 9 Haemoglobinon pathes, 12-37 Haemoglobins, human, 1 HARRIS, H.: Genetic heterogeneity in inherited disease, 32 Haemoglobinopathies, 12-37 Haemoglobins, human, 1 Harmoglobins, human, 1 Haemoglobins, human, 1 Hae	BROCK, D. J. H.: Frenatai diagnosis and genetic counselling, 150	
Chondroitin 6-sulphaturia, 74 CLAYTON, B. E.! Population screening, 145 Community, problems affecting, 145-163 Cystic fibrosis, screening for, 148 Debranching enzyme deficiency, 114 Enzyme deficiencies, 128-144 Enzyme deficiency, 142 Enzyme defic	Chondroitin 4-sulphaturia, 73	
Debranching enzyme deficiency, 114 Enzyme deficiencies, different degrees of, in sphingolipidoses, 100 — in erythrocytes, 128-144 — oysgen affinity changes in, physiological consequences of, 142 — in sphingolipidoses, 96 — mutants, increased steady-state concentration with slight residual activity, 42 — low activity in, benefit of small increases in, 43 Erythrocyte enzyme deficiencies, 128-144 — yoxygen affinity changes in, physiological consequences of, 142 — oysygen affinity changes in, physiological consequences of, 142 — oysygen affinity changes in, physiological consequences of, 142 — protein synthesis in, 5 — protein synthesis in, 6 — protein synthesis in, 5 — protein synthesis in, 5 — protein synthesis in, 6 — in herapeuric attempts in, 69 Hypoxanthine guanine phosphoribosyltransferase deficiency, 51 Inherited disease, 66 — characteria, 82-4 — in red cells and other tissues, 122 — vitamin-responsive, 38 Inherited disease, 61 Histidianemis, screening for, 147 Guitalianemis, screening for, 146 Hotelero		at gene level. 7
Debranching enzyme deficiency, 114 Enzyme deficiencies, different degrees of, in sphingolipidoses, 100 — in erythrocytes, 128-144 — oysgen affinity changes in, physiological consequences of, 142 — in sphingolipidoses, 96 — mutants, increased steady-state concentration with slight residual activity, 42 — low activity in, benefit of small increases in, 43 Erythrocyte enzyme deficiencies, 128-144 — yoxygen affinity changes in, physiological consequences of, 142 — oysygen affinity changes in, physiological consequences of, 142 — oysygen affinity changes in, physiological consequences of, 142 — protein synthesis in, 5 — protein synthesis in, 6 — protein synthesis in, 5 — protein synthesis in, 5 — protein synthesis in, 6 — in herapeuric attempts in, 69 Hypoxanthine guanine phosphoribosyltransferase deficiency, 51 Inherited disease, 66 — characteria, 82-4 — in red cells and other tissues, 122 — vitamin-responsive, 38 Inherited disease, 61 Histidianemis, screening for, 147 Guitalianemis, screening for, 146 Hotelero		— , posttranscriptional, 9
Debranching enzyme deficiency, 114 Enzyme deficiencies, different degrees of, in sphingolipidoses, 100 — in erythrocytes, 128-144 — oysgen affinity changes in, physiological consequences of, 142 — in sphingolipidoses, 96 — mutants, increased steady-state concentration with slight residual activity, 42 — low activity in, benefit of small increases in, 43 Erythrocyte enzyme deficiencies, 128-144 — yoxygen affinity changes in, physiological consequences of, 142 — oysygen affinity changes in, physiological consequences of, 142 — oysygen affinity changes in, physiological consequences of, 142 — protein synthesis in, 5 — protein synthesis in, 6 — protein synthesis in, 5 — protein synthesis in, 5 — protein synthesis in, 6 — in herapeuric attempts in, 69 Hypoxanthine guanine phosphoribosyltransferase deficiency, 51 Inherited disease, 66 — characteria, 82-4 — in red cells and other tissues, 122 — vitamin-responsive, 38 Inherited disease, 61 Histidianemis, screening for, 147 Guitalianemis, screening for, 146 Hotelero		———, ——, translational, 9
Debranching enzyme deficiency, 114 Enzyme deficiencies, different degrees of, in sphingolipidoses, 100 — in erythrocytes, 128-144 — — oxygen affinity changes in, physiological consequences of, 142 — — in sphingolipidoses, 96 mutants, increased steady-state concentration with slight residual activity, 42 — — low activity in, benefit of small increases in, 43 Erythrocyte enzyme deficiencies, 128-144 — — oxygen affinity changes in, physiological consequences of, 142 — oxygen affinity changes in, physiological consequences, 0xygen affinity changes in, physiological consequences of, 142 — oxygen affinity changes in, physiological consequences, 0xygen affinity in the red cell enzyme defects, 142 Hutten disease, 70 Hurler disease, 76 — oxygen affinity in the red cell enzyme defects, 142 Hutter disease, 70 Hurler disease, 76 — oxygen affinity in the red cell enzyme defects, 142 Hutter disease, 70 Hurler disease, 70 Hu	Cystic fibrosis, screening for, 148	Haemoglobinopathies, 12-37
Enzyme deficiencies, different degrees of, in sphingolipidoses, 100 — in erythrocytes, 128-144 — — oxygen affinity changes in, physiological consequences of, 142 — in sphingolipidoses, 96 — mutants, increased steady-state concentration with slight residual activity, 42 — oxygen affinity changes in, physiological consequences of, 142 — low activity in, benefit of small increases in, 43 Erythrocyte enzyme deficiencies, 128-144 — oxygen affinity changes in, physiological consequences of, 142 — oxygen affinity changes in, physiological consequences of, 142 — precursors, protein and nucleic acid synthesis in, general pattern of, of, 2 — protein synthesis in, 5 — proteins data in, 82 — chinical features of, 64 — proteins synthesis in, 69 Hypoxanthine guanine phosphoribosyltransferase deficiency, 53 Inherited disease, genetic heterogeneity in, 32 — proteins and sulphydryl reactions, 123 — asymmetrical disease, 92 — in inherited disease, 32 Glucose-6-phosphatate dehydrogenase, deficiency, 134 — in inherited metabolic disease, 12 Heterozygosity in inherited metabolic disease, 12 Heterozygosity in inherited metabolic disease, 12 Huter disease, 70 Hutler disease, 70 — proteins synthesis in proteins and mucolipidoses in oxygen affinity in the red cell enzyme defects, 142 Hutter disease, 70 — proteins synthesis in proteins and mucolipidoses in oxygen affinity	D	Haemoglobins, human, 1
Heterogeneity. See Genetic heterogeneity — in erythrocytes, 128-144 — in sphingolipidoses, 96 mutants, increased steady-state concentration with slight residual activity, 42 — , low activity in, benefit of small increases in, 43 Erythrocyte enzyme deficiencies, 128-144 — , low activity in, benefit of small increases in, 43 Erythrocyte enzyme deficiencies, 128-144 — , oxygen affinity changes in, physiological consequences of, 142 — precursors, protein and nucleic acid synthesis in, general pattern of, 2 Erythrocytes, isozyme patterns in, 122 — protein synthesis in, 5 — pyruvate kinase in, 128 Erythropicesis, ineffective, in β-thalassaemia major, 13 Fucosidosis, 82 — enzymology of, 83 — pathological data in, 82 Galactosaemia, screening for, 147 Gy, Gangliosidosis, 79 — chemistry of, 81 — cinical features of, 82 — enzymology of, 81 — counselling and prenatal diagnosis, 150 disease. See Inherited diseases: Metabolic disease inherited heterogeneity in glucose-6-phosphate dehydrogenase deficiency, 134, 135 — deficiency, future prospects for study of, 136 — system, role in mappingling desage, genetic heterogeneity in, particulated and the future deficiency, 134 — in inherited disease, genetic heterogeneity in particulated deficiencies, 142 HHETOROMAN, D. A.: Isozymes, 122 HHETOROMAN, D. A.: I	Debranching enzyme deficiency, 114	HARRIS, H.: Genetic heterogeneity in inherited disease, 32
— in erythrocytes, 128-144 — in sphingolipidoses, 96 — mutants, increased steady-state concentration with slight residual activity, 42 — in sphingolipidoses, 96 — mutants, increased steady-state concentration with slight residual activity, 42 — in sphingolipidoses, 96 — mutants, increased steady-state concentration with slight residual activity, 42 — in low activity in, benefit of small increases in, 43 Erythrocyte enzyme deficiencies, 128-144 — or overgen affinity changes in, physiological consequences of, 142 — or overgen affinity changes in, physiological consequences of, 142 — precursors, protein and nucleic acid synthesis in, general pattern of, 2 Erythrocytes, isozyme patterns in, 122 — protein synthesis in, 5 — pyruvate kinase in, 128 Erythropoiesis, ineffective, in β-thalassaemia major, 13 Fucosidosis, 82 — clinical features of, 82 — cinical features of, 81 — cinical and biological data in, 80 — crymology of, 80 Galactosaemia, screening for, 147 Gutantine gualine g	Enzyme deficiencies different degrees of in enhingelinidoses 100	
sequences of, 142 — in sphingolipidoses, 96 mutants, increased steady-state concentration with slight residual activity, 42 — , low activity in, benefit of small increases in, 43 Erythrocyte enzyme deficiencies, 128-144 — on yangen affinity changes in, physiological consequences of, 142 — precursors, protein and nucleic acid synthesis in, general pattern of, 2 Erythrocytes, isozyme patterns in, 122 — protein synthesis in, 5 — pyruvate kinase in, 128 Erythropicesis, ineffective, in β-thalassaemia major, 13 Fucosidosis, 82 — clinical features of, 82 — clinical and biological data in, 82 Galactosaemia, screening for, 147 G _{M-} Gangliosidosis, 79 — chemistry of, 81 — clinical and biological data in, 80 — enzymology of, 81 — counselling and prenatal diagnosis, 150 disease. See Inherited diseases; Metabolic disease inherited heterogeneity in glucose-6-phosphate dehydrogenase deficiency, 134, 135 — deficiency, future prospects for study of, 136 — system, role in metabolism, disease, genetic heterogeneity in, 32 — separational, 123 — asymmetrical, 125 — secondary, 123 — submit structure of, 124 Lesch-Nyhan syndrome, 55 Liver phosphorylase and related deficiencies, 116 Lyosomoal acid malates' deficiency, 113 — diseases, genetic heterogene	in erythrocytes 128-144	
sequences of, 142 — in sphingolipidoses, 96 mutants, increased steady-state concentration with slight residual activity, 42 — low activity in, benefit of small increases in, 43 Erythrocyte enzyme deficiencies, 128-144 — oyegen affinity changes in, physiological consequences of, 142 — oxygen affinity changes in, physiological consequences of, 142 — oxygen affinity changes in, physiological consequences of, 142 — oxygen affinity changes in, physiological consequences of, 142 — oxygen affinity changes in, physiological consequences of, 142 — oxygen affinity changes in, physiological consequences of, 142 — oxygen affinity changes in, physiological consequences of, 142 — oxygen affinity changes in, physiological consequences of changes in oxygen affinity in the red cell enzyme defects, 142 — Hunter disease, 70 Hurler disease, 6 — oxygen affinity in the red cell enzyme defects, 142 — Hunter disease, 60 — oxygen affinity in the red cell enzyme defects, 142 — Hunter disease, 60 — oxygen affinity changes in, physiological consequences of changes in oxygen affinity in the red cell enzyme defects, 142 — Hunter disease, 60 — oxygen affinity changes in, physiological consequences of changes in oxygen affinity in the red cell enzyme defects, 142 — Hunter disease, 60 — oxygen affinity changes in, physiological consequences of changes in oxygen affinity in the red cell enzyme defects, 142 — Hunter disease, 60 — oxygen affinity changes in, physiological consequences of, 66 — oxygen affinity changes in, 69 — oxygen affinity changes in, 69 — oxygen affinity changes, 66 — oxygen affinity changes in, 69 — oxygen affinity changes, 66 — oxygen affini	ovvgen affinity changes in physiological con-	
— in sphingolipidoses, 96 — mutants, increased steady-state concentration with slight residual activity, 42 — —, low activity in, benefit of small increases in, 43 Erythrocyte enzyme deficiencies, 128-144 — —, oxygen affinity changes in, physiological consequences of, 142 — precursors, protein and nucleic acid synthesis in, general pattern of, 2 — protein synthesis in, 5 — pyruvate kinase in, 128 Erythrocytes, isozyme patterns in, 122 — protein synthesis in, 5 — pyruvate kinase in, 128 Erythropoiesis, ineffective, in β-thalassaemia major, 13 Fucosidosis, 82 — clinical features of, 82 — clinical features of, 83 — pathological data in, 82 Galactosaemia, screening for, 147 GM _{xf} -Gangliosidosis, 79 — chemistry of, 81 — clinical and biological data in, 80 — enzymology of, 81 — clinical and biological data in, 80 — enzymology of, 81 — counselling and prenatal diagnosis, 150 disease. See Inherited disease; Metabolic disease inherited heterogeneity in glucose-6-phosphate dehydrogenase deficiency, 113 Glucose-6-phosphate deficiency, 54, 112 Glucose-6-phosphate deficiency, 54, 112 Glucose-6-phosphate deficiency, 54, 112 Glucose-6-phosphate deficiency, 74 Glutathione reductase activity, increase in, 54 Glycogen metabolism, disorders of, 108 HOPKINSON, D. A.: Isozymes, 122 HUBENS, E. R.: The physiological consequences of changes in oxygen affinity in the red cell enzyme defects, 142 Hunter disease, 70 Hunter disease, 70 — enzymology of, 66 ——, chemistry of, 68 ——, chemistry of, 68 ——, cherosistry of, 68 ——, cherosistry of, 69 ——, petrogenis of, 134 ——, setrogenis of, 134 ——, hetrogenis of, 134 B-Glucuronidase deficiency, 74 Glutathione reductase activity, increase in, 54 Glycogen metabolism, disorders of, 108 HOPKINSON, D. A.: Interdical entres of, 66 ——, chemistry of, 68 ——, chemistry of, 81 ——, cherogenic of, 134 ——, cherogenic of, 134 ——, cherogenic of, 134 ——, hetrogenic of, 134 ——, hetrogenic of, 134 ——,		
mutants, increased steady-state concentration with slight residual activity, 42 ————————————————————————————————————		
activity, 42 — — — low activity in, benefit of small increases in. 43 Erythrocyte enzyme deficiencies, 128-144 — — — oxygen affinity changes in, physiological consequences of, 142 — precursors, protein and nucleic acid synthesis in, general pattern of, 2 Erythrocytes, isozyme patterns in, 122 — protein synthesis in, 5 — pyruvate kinase in, 128 Erythropoiesis, ineffective, in β-thalassaemia major, 13 Fucosidosis, 82 — clinical features of, 82 — clinical features of, 82 — enzymology of, 83 — pathological data in, 82 Galactosaemia, screening for, 147 G _{M1} -Gangliosidosis, 79 — enemistry of, 81 — enzymology of, 81 — enzymology of, 80 Genetic control of protein synthesis, 1 — counselling and prenatal diagnosis, 150 — disease, See Inherited disease; Metabolic disease inherited heterogeneity in glucose-6-phosphate dehydrogenase deficiency, 134 — — in inherited disease, 32 Glucose-6-phosphatase deficiency, 54, 112 Glucose-6-phosphatase deficiency, 74, 134 β-Glucuronidase deficiency, 74 Glutathione reductase activity, increase in, 54 Glycogen metabolism, disorders of, 108 Hunter disease, 70 Hunter disease, 76 — enzymology of, 68 — enzymology of, 69 — heterapeutic attempts in, 69 — heterapeutic attempts in, 69 — heterogeneity in β-thalassaemia major, 13 Horincal features of, 66 — enzymology of, 67 — prenatal diagnosis and heterozygote detection in, 69 — heterapeutic attempts in, 69 — enzymology of, 67 — prenatal diagnosis and heterozygote detection in, 69 — heterapeutic attempts in, 69 — heterapeutic attempts in, 69 — anymology of, 67 — prenatal diagnosis and heterozygote detection in, 69 — enzymology of, 67 — prenatal diagnosis and heterozygote deficiency, 53 Isozume, 122 — oxincal features of, 68 — enzymology of, 67 — prenatal diagnosis and heterozygote deficiency, 13 Isozume, 122 — oxincal features of, 68 — enzymology of, 69 — enzymology o		
Erythrocyte nazyme deficiencies, 128-144 — o, oxygen affinity changes in, physiological consequences of, 142 — precursors, protein and nucleic acid synthesis in, general pattern of, 2 Erythrocytes, isozyme patterns in, 122 — protein synthesis in, 5 — pyrvate kinase in, 128 Erythropoiesis, ineffective, in β-thalassaemia major, 13 Fucosidosis, 82 — clinical features of, 63 — may mology of, 69 — morphology of, 69 — prenatal diagnosis and heterozygote detection in, 69 — therapeutic attempts in, 69 — therapeutic attempts in, 69 — therapeutic attempts in, 69 — prenatal diagnosis and heterozygote detection in, 69 — therapeutic attempts in, 69 — prenatal diagnosis and heterozygote detection in, 69 — therapeutic attempts in, 69 — prenatal diagnosis and heterozygote detection in, 69 — therapeutic attempts in, 69 — prenatal diagnosis and heterozygote detection in, 69 — therapeutic attempts in, 69 — prenatal diagnosis and heterozygote detection in, 69 — prenatal diagnosis and heterozygote detect		
Hurler disease, 66 —, oxygen affinity changes in, physiological consequences of, 142 — precursors, protein and nucleic acid synthesis in, general pattern of, 2 Erythrocytes, isozyme patterns in, 122 —, protein synthesis in, 5 —, pyruvate kinase in, 128 Erythropoiesis, ineffective, in β-thalassaemia major, 13 Fucosidosis, 82 —, clinical features of, 82 —, clinical features of, 82 —, enzymology of, 83 —, pathological data in, 82 Galactosaemia, screening for, 147 GM ₁ -Gangliosidosis, 79 —, chemistry of, 68 ——, seemath of the terrogeneity in glucose-6-phosphate dehydrogenase deficiency, 134 —— in inherited disease; Metabolic disease inherited heterogeneity in glucose-6-phosphate dehydrogenase deficiency, 134 β-Glucuronidase deficiency, 54, 112 Glucose-6-phosphate dehydrogenase, defective molecular variants of, 143, 135 —— heterogeneity of, 134 β-Glucuronidase deficiency, 74 Glutathione reductase activity, increase in, 54 Glycogen metabolism, disorders of, 108 Hurler disease, 66 ——, chemistry of, 68 ——, elaymology of, 67 ——, prenatal diagnosis, and heterozygote detection in, 69 ——, prenatal diagnosis and heterozygote detection in, 69 ——, prenatal diagnosis and heterozygote detection in, 69 ——, prenatal diagnosis type II, 75 Inherited disease, genetic heterogeneity in, 32 ——, symmetrical, 125 Inherited disease, prentic heterogeneity in, 32 ——, asymmetrical, 125 ——, asymmetrical, 125 ——, asymmetrical, 123 ——, secondary, 122 ——, subunit structure of, 124 KAPLAN, J. C.: Defective molecular variants of glucose-6-phosphate dehydrogenase deficiency, 113 disease, 5e Hurler disease, 66 ——,enzymology of, 69 Hypoxanthine guanine phosphoribosyltransferase deficiency, 53 It-cells in mucolipidoses type II, 75 Inherited disease, genetic heterogeneity in, 32 ——, asymmetrical, 125 Inherited disease, genetic heterogeneity in, 32 ——, asymmetrical, 125 ——, asymmetrical, 125 ——, asymmetrical, 125 ——, asymmetrical, 125 ——, secondary, 122 ——, subunit structure of, 124 KAPLAN, J. C.: Defective molecular variants of glucose-6-ph	——, low activity in, benefit of small increases in, 43	
 — , oxygen athnity changes in, physiological consequences of, 142 — precursors, protein and nucleic acid synthesis in, general pattern of, 2 Erythrocytes, isozyme patterns in, 122 — , protein synthesis in, 5 — , pyroutate kinase in, 128 Erythropoiesis, ineffective, in β-thalassaemia major, 13 Fucosidosis, 82 — , clinical features of, 82 — , clinical features of, 82 — , cinical affeatures of, 82 — , pathological data in, 82 Galactosaemia, screening for, 147 G M₁ - Gangliosidosis, 79 — , clinical and biological data in, 80 — , enzymology of, 81 — , clinical and biological data in, 80 — enzymology of, 81 — conuselling and prenatal diagnosis, 150 — disease. See Inherited disease; Metabolic disease inherited heterogeneity in glucose-6-phosphate dehydrogenase deficiency, 134 — — in inherited disease, 32 Glucose-6-phosphatae deficiency, 54, 112 Glucose-6-phosphatae dehydrogenase, defective molecular variants of, 134, 135 — — , heterogeneity of, 134 B-Glucuronidase deficiency, 74 Glutathione reductase activity, increase in, 54 Glycogen metabolism, disorders of, 108 — , chemistry of, 68 — , clinical features of, 66 — , enzymology of, 69 — , morphology Hypoxanthine guanine phosphoribosyltransferase deficiency, 53 II-cells in mucolipidosis type II, 75 Inherited disease, genetic heterogeneity in, 32 — , vitamin-responsive, 38 Isozymes, 125 — in red cells and other tissues, 122 Isozymes, 122 — , secondary, 122 — , secondary, 122 — , secondary, 122 — , subunit structure of, 124 KAPLAN, J. C.: Defective molecular variants of glucose-6-phosphate deficiency, 51 — (sherital disease, 12) Malformations, congenital, 153 Mannosidosi	Erythrocyte enzyme deficiencies, 128-144	
— precursors, protein and inducted actur symmess in, general pattern of, 2 Erythrocytes, isozyme patterns in, 122 — protein synthesis in, 5 — pyruvate kinase in, 128 Erythropoiesis, ineffective, in β-thalassaemia major, 13 Fucosidosis, 82 —, clinical features of, 82 —, clinical features of, 82 —, clinical features of, 82 —, chemistry of, 81 —, clinical and biological data in, 82 Galactosaemia, screening for, 147 GM₁-Gangliosidosis, 79 —, chemistry of, 81 —, clinical and biological data in, 80 —, enzymology of, 81 —, pathology of, 81 — pathology of, 81 — eounselling and prenatal diagnosis, 150 — disease. See Inherited disease; Metabolic disease inherited heterogeneity in glucose-6-phosphate dehydrogenase deficiency, 134 — in inherited disease, 32 Glucose-6-phosphate dehydrogenase, defective molecular variants of, 134, 135 — deficiency, future prospects for study of, 136 — heterogeneity of, 134 β-Glucuronidase deficiency, 74 Glutathione reductase activity, increase in, 54 Glycogen metabolism, disorders of, 108 — enzymology of, 69 — merphology of, 69 — merphology of, 67 — prenatal diagnosis and heterozygote detection in, 69 — heterogencity in, 90 — heterogencity in, 32 — vitamin-responsive, 38 Isoenzymes, role in sphingolipidoses, 97 Isozyme patterns and sulphydryl reactions, 123 — symmetrical, 125 — in red cells and other tissues, 122 Isozymes, 122 — conformational, 123 — due to multiple alleles, at single locus, 124 — gene loci, 125 — secondary, 122 — submit structure of, 124 KAPLAN, J. C.: Defective molecular variants of glucose-6-phosphate dehydrogenase and methaemoglobin reductase, 134 Lesch-Nyhan syndrome, 55 Liver phosphorylase and related deficiencies, 116 Lyersomory and methaemoglobin reductase, 134 Malformations, congenital, 153 Mannosidosis, 84 Maroteaux-Lamy disease, 72		
Further precisions, protein and inducted active synthesis in, general pattern of, 2 Erythrocytes, isozyme patterns in, 122 —, protein synthesis in, 5 —, pyruvate kinase in, 128 Erythropolesis, ineffective, in β-thalassaemia major, 13 Fucosidosis, 82 —, clinical features of, 82 —, clinical features of, 82 —, clinical features of, 82 —, chemistry of, 81 —, clinical and biological data in, 82 Galactosaemia, screening for, 147 GM₁-Gangliosidosis, 79 —, chemistry of, 81 —, clinical and biological data in, 80 —, enzymology of, 81 —, pathology of, 81 — ocunselling and prenatal diagnosis, 150 — disease. See Inherited disease; Metabolic disease inherited heterogeneity in glucose-6-phosphate dehydrogenase deficiency, 134 — in inherited disease, 32 Glucose-6-phosphate dehydrogenase, defective molecular variants of, 134, 135 — deficiency, future prospects for study of, 136 — heterogeneity of, 134 β-Glucuronidase deficiency, 74 Glutathione reductase activity, increase in, 54 Glycogen metabolism, disorders of, 108 - maymology of, 69 —, prenatal diagnosis and heterozygote detection in, 69 —, prenatal diagnosis and heterozygote detection in, 69 —, prenatal diagnosis and heterozygote detection in, 69 —, therapeutic attempts in, 69 Hypoxantine guanine phosphoribosyltransferase deficiency, 53 I-cells in mucolipidosis type II, 75 Inherited disease, genetic heterogeneity in, 32 —— is primarine guanine phosphoriplososyltransferase deficiency, 123 —— is pred cells and other tissues, 123 —— in red cells and other tissues, 122 —— onformational, 123 —— due to multiple alleles, at single locus, 124 ————————————————————————————————————		, clinical features of, 66
Crythrocytes, isozyme patterns in, 122 —, protein synthesis in, 5 —, pyruvate kinase in, 128 Erythropoiesis, ineffective, in β-thalassaemia major, 13 Fucosidosis, 82 —, clinical features of, 82 —, enzymology of, 83 —, pathological data in, 82 Galactosaemia, screening for, 147 G _{M₁} -Gangliosidosis, 79 —, chemistry of, 81 —, clinical and biological data in, 80 —, enzymology of, 80 Genetic control of protein synthesis, 1 — counselling and prenatal diagnosis, 150 — disease. See Inherited disease; Metabolic disease inherited — heterogeneity in glucose-6-phosphate dehydrogenase deficiency, 134 — in inherited disease, 32 Glucose-6-phosphates deficiency, 54, 112 Glucose-6-phosphates dehydrogenase, defective molecular variants of, 134, 135 — deficiency, future prospects for study of, 136 — heterogeneity of, 134 β-Glucuronidase deficiency, 74 Glucuronidase deficiency, 74 Glucuro		, enzymology of, 69
—, protein synthesis in, 128 —, pyruvate kinase in, 128 Erythropoiesis, ineffective, in β-thalassaemia major, 13 Fucosidosis, 82 —, clinical features of, 82 —, clinical features of, 82 —, enzymology of, 83 —, pathological data in, 82 Galactosaemia, screening for, 147 GM₁-Gangliosidosis, 79 —, chemistry of, 81 —, clinical and biological data in, 80 —, enzymology of, 81 —, pathology of, 80 —, enzymology of, 81 —, clinical and biological data in, 80 —, enzymology of, 81 —, pathology of, 80 —, enzymology of, 81 —, pathology of, 80 —, enzymology of, 81 — in inherited disease, 32 Glucose-6-phosphate dehydrogenase deficiency, 134 — in inherited disease, 32 Glucose-6-phosphate dehydrogenase, defective molecular variants of, 134, 135 — deficiency, future prospects for study of, 136 — heterogeneity of, 134 β-Glucuronidase deficiency, 74 Glutathione reductase activity, increase in, 54 Glycogen metabolism, disorders of, 108 —, protein synthesis in, 52 —, therapetuic attempts in, 69 Hypoxanthine guanine phosphoribosyltransferase deficiency, 53 Inherited disease, genetic heterogeneity in, 32 —, vitamin-responsive, 38 Isoenzymes, role in sphingolipidoses, 97 Isozyme patterns and sulphydryl reactions, 123 ——in red cells and other tissues, 122 Isozyme, role in mucolipidoses, 122 ——, secondary, 122 ——, secondary, 122 ——, secondary, 123 ——, subunit structure of, 124 KAPLAN, J. C.: Defective molecular variants of glucose-6-phosphate dehydrogenase and methaemoglobin reductase, 134 Lesch-Nyhan syndrome, 55 Liver phosphorylase and related deficiencies, 116 Lyosomal 'acid maltase' deficiency, 113 —— diseases, inborn, 64 — system, role in mucolipidoses and mucolipidoses, 87 Mannosidosis, 84 Maroteaux-Lamy disease, 72 Maroteaux-Lamy disease, 72 Maroteaux-Lamy disease, 72 Maroteaux-Lamy disease, 72		——, morphology of, 67
Fucosidosis, 82 —, clinical features of, 82 —, enzymology of, 83 —, pathological data in, 82 Galactosaemia, screening for, 147 GM ₁ -Gangliosidosis, 79 —, clinical and biological data in, 80 —, enzymology of, 81 —, clinical and biological data in, 80 —, enzymology of, 81 —, clinical and biological data in, 80 —, enzymology of, 81 —, conselling and prenatal diagnosis, 150 — disease. See Inherited disease; Metabolic disease inherited — heterogeneity in glucose-6-phosphate dehydrogenase deficiency, 134 — in inherited disease, 32 Glucose-6-phosphate dehydrogenase, defective molecular variants of, 134, 135 — deficiency, future prospects for study of, 136 — m, heterogeneity of, 134 β-Glucuronidase deficiency, 74 Glutathione reductase activity, increase in, 54 Glycogen metabolism, disorders of, 108 Hypoxanthine guanine phosphoribosyltransferase deficiency, 53 I-cells in mucolipidosis type II, 75 Inherited disease, genetic heterogeneity in, 32 ——, vitamin-responsive, 18 Isoenzymes, role in sphingolipidoses, 97 Isozymes, role in sphingolipidoses, 97 Isozymes, role in sphingolipidoses, 123 ——, asymmetrical, 125 —— in red cells and other tissues, 122 Isozymes, 122 ——, conformational, 123 —— deteleles, at single locus, 124 ————————————————————————————————————	Erythrocytes, isozyme patterns in, 122	, prenatal diagnosis and heterozygote detection in, 69
Fucosidosis, 82 —, clinical features of, 82 —, enzymology of, 83 —, pathological data in, 82 Galactosaemia, screening for, 147 GM1-Gangliosidosis, 79 —, clinical and biological data in, 80 —, enzymology of, 81 —, clinical and biological data in, 80 —, enzymology of, 81 —, clinical and biological data in, 80 —, enzymology of, 81 —, conselling and prenatal diagnosis, 150 — diseases. See Inherited disease; Metabolic disease inherited — heterogeneity in glucose-6-phosphate dehydrogenase deficiency, 134 — in inherited disease, 32 Glucose-6-phosphate dehydrogenase, defective molecular variants of, 134, 135 — deficiency, future prospects for study of, 136 — deficiency, 74 Glucuronidase deficiency, 74 Glucuro	—, protein synthesis in, 5	, therapeutic attempts in, 69
Fucosidosis, 82 —, clinical features of, 82 —, enzymology of, 83 —, pathological data in, 82 Galactosaemia, screening for, 147 Ga _{M-} -Gangliosidosis, 79 —, clinical and biological data in, 80 —, enzymology of, 81 —, clinical and biological data in, 80 —, enzymology of, 81 —, pathology of, 80 Genetic control of protein synthesis, 1 — counselling and prenatal diagnosis, 150 — disease. See Inherited disease; Metabolic disease inherited — heterogeneity in glucose-6-phosphate dehydrogenase deficiency, 134 — in inherited disease, 32 Glucose-6-phosphatae deficiency, 54, 112 Glucose-6-phosphate dehydrogenase, defective molecular variants of, 134, 135 — deficiency, future prospects for study of, 136 — must live phosphorylase and related deficiencies, 116 Lysosomal 'acid maltase' deficiency, 113 — diseases, inborn, 64 — system, role in mucopolysaccharidoses and mucolipidoses, 87 Malformations, congenital, 153 Mannosidosis, 84 Marotealwa badicanned, prevalence of inherited metabolic disease		Hypoxanthine guanine phosphoribosyltransferase deficiency, 53
Fucosidosis, 82 —, clinical features of, 82 —, enzymology of, 83 —, pathological data in, 82 Galactosaemia, screening for, 147 Galactosaemia, screening for, 147 Galactosaemia, screening for, 147 Galactosaemia, screening for, 147 Gilinical and biological data in, 80 —, clinical and biological data in, 80 —, enzymology of, 81 —, pathology of, 81 — counselling and prenatal diagnosis, 150 — disease. See Inherited disease; Metabolic disease inherited — heterogeneity in glucose-6-phosphate dehydrogenase deficiency, 134 — in inherited disease, 32 Glucose-6-phosphates deficiency, 54, 112 Glucose-6-phosphate dehydrogenase, defective molecular variants of, 134, 135 — deficiency, future prospects for study of, 136 — heterogeneity of, 134 β-Glucuronidase deficiency, 74 Glutathione reductase activity, increase in, 54 Glycogen metabolism, disorders of, 108 Inherited disease, genetic heterogeneity in, 32 —, vitamin-responsive, 38 Isoenzymes, role in sphingolipidoses, 97 Isozyme patterns and sulphydryl reactions, 123 ——, asymmetrical, 125 ——, asymme	Etythiopolesis, meneetive, in p-maiassaemia major, 15	Leelle in mucolinidosis type II 75
— , clinical features of, 82 — , enzymology of, 83 — , pathological data in, 82 Galactosaemia, screening for, 147 G _{M1} -Gangliosidosis, 79 — , chemistry of, 81 — , clinical and biological data in, 80 — , enzymology of, 80 Genetic control of protein synthesis, 1 — counselling and prenatal diagnosis, 150 — disease. See Inherited disease; Metabolic disease inherited — heterogeneity in glucose-6-phosphate dehydrogenase deficiency, 134 — — in inherited disease, 32 Glucose-6-phosphatase deficiency, 54, 112 Glucose-6-phosphatase deficiency, 54, 112 Glucose-6-phosphate dehydrogenase, defective molecular variants of, 134, 135 — — deficiency, future prospects for study of, 136 — — heterogeneity of, 134 β-Glucuronidase deficiency, 74 Glutathione reductase activity, increase in, 54 Glycogen metabolism, disorders of, 108 — (sincial and sulphydryl reactions, 123 — asymmetrical, 125 — in red cells and other tissues, 122 Isozymes, 70le in sphingolipidoses, 97 Isozyme patterns and sulphydryl reactions, 123 — asymmetrical, 125 — in red cells and other tissues, 122 Isozymes, 70le in sphingolipidoses, 97 Isozyme patterns and sulphydryl reactions, 123 — asymmetrical, 125 — in red cells and other tissues, 122 Isozymes, 70le in sphingolipidoses, 97 Isozyme patterns and sulphydryl reactions, 123 — osymmetrical, 125 — in red cells and other tissues, 122 Isozymes, 70le in sphingolipidoses, 97 Isozyme patterns and sulphydryl reactions, 123 — osymmetrical, 125 — in red cells and other tissues, 122 Isozymes, 70le in sphingolipidoses, 97 Isozymes, 70le clusterios, asymmetrical, 125 — in red cells and other tissues, 122 Isozymes, 70le	Fucosidosis, 82	
—, enzymology of, 83 —, pathological data in, 82 Galactosaemia, screening for, 147 G _{M1} -Gangliosidosis, 79 —, chemistry of, 81 —, clinical and biological data in, 80 —, enzymology of, 81 —, pathology of, 81 —, pathology of, 81 —, pathology of, 81 — counselling and prenatal diagnosis, 150 — disease. See Inherited disease: Metabolic disease inherited — heterogeneity in glucose-6-phosphate dehydrogenase deficiency, 134 — in inherited disease, 32 Glucose-6-phosphate dehydrogenase, defective molecular variants of, 134, 135 — deficiency, future prospects for study of, 136 — heterogeneity of, 134 β-Glucuronidase deficiency, 74 Glutathione reductase activity, increase in, 54 Glycogen metabolism, disorders of, 108 Isoenzymes, role in sphingolipidoses, 97 Isozyme patterns and sulphydryl reactions, 123 — any symmetrical, 125 — in red cells and other tissues, 122 Isozymes, 122 — oin red cells and other tissues, 122 Isozymes, 1	, clinical features of, 82	
Galactosaemia, screening for, 147 G _{M1} -Gangliosidosis, 79 —, chemistry of, 81 —, clinical and biological data in, 80 —, enzymology of, 81 —, pathology of, 80 Genetic control of protein synthesis, 1 — counselling and prenatal diagnosis, 150 — disease. See Inherited disease; Metabolic disease inherited — heterogeneity in glucose-6-phosphate dehydrogenase deficiency, 134 — in inherited disease, 32 Glucose-6-phosphates deficiency, 54, 112 Glucose-6-phosphates deficiency, 54, 112 Glucose-6-phosphate dehydrogenase, defective molecular variants of, 134, 135 — deficiency, future prospects for study of, 136 — heterogeneity of, 134 β-Glucuronidase deficiency, 74 Glutathione reductase activity, increase in, 54 Glycogen metabolism, disorders of, 108 Isozyme patterns and sulphydryl reactions, 123 — asymmetrical, 125 — in red cells and other tissues, 122 Isozymes, 122 —, conformational, 123 — due to multiple alleles, at single locus, 124 — ———————————————————————————————————	—, enzymology of, 83	
Galactosaemia, screening for, 147 GM ₁ -Gangliosidosis, 79 —, chemistry of, 81 —, clinical and biological data in, 80 —, enzymology of, 81 —, pathology of, 80 Genetic control of protein synthesis, 1 — counselling and prenatal diagnosis, 150 — disease. See Inherited disease; Metabolic disease inherited — heterogeneity in glucose-6-phosphate dehydrogenase deficiency, 134 — in inherited disease, 32 Glucose-6-phosphatase deficiency, 54, 112 Glucose-6-phosphatase deficiency, 54, 112 Glucose-6-phosphate dehydrogenase, defective molecular variants of, 134, 135 — deficiency, future prospects for study of, 136 — heterogeneity of, 134 β-Glucuronidase deficiency, 74 Glutathione reductase activity, increase in, 54 Glycogen metabolism, disorders of, 108 — asymmetrical, 125 — in red cells and other tissues, 122 Isozymes, 122 —, conformational, 123 — deu to multiple alleles, at single locus, 124 — gene loci, 125 —, secondary, 122 —, subunit structure of, 124 KAPLAN, J. C.: Defective molecular variants of glucose-6-phosphate dehydrogenase and methaemoglobin reductase, 134 Lesch-Nyhan syndrome, 55 Liver phosphorylase and related deficiencies, 116 Lysosomal 'acid maltase' deficiency, 113 — diseases, inborn, 64 — system, role in mucopolysaccharidoses and mucolipidoses, 87 Malformations, congenital, 153 Mannosidosis, 84 Marotelly-head-gravelence of inherited metabolic disease	, pathological data in, 82	
Gur-Gangliosidosis, 79 —, chemistry of, 81 —, clinical and biological data in, 80 —, enzymology of, 81 —, pathology of, 80 Genetic control of protein synthesis, 1 — counselling and prenatal diagnosis, 150 — disease. See Inherited disease; Metabolic disease inherited — heterogeneity in glucose-6-phosphate dehydrogenase deficiency, 134 — in inherited disease, 32 Glucose-6-phosphates deficiency, 54, 112 Glucose-6-phosphate dehydrogenase, defective molecular variants of, 134, 135 — deficiency, future prospects for study of, 136 — heterogeneity of, 134 β-Glucuronidase deficiency, 74 Glutathione reductase activity, increase in, 54 Glycogen metabolism, disorders of, 108 Isozymes, 122 —, conformational, 123 — due to multiple alleles, at single locus, 124 — gene loci, 125 —, secondary, 122 —, subunit structure of, 124 KAPLAN, J. C.: Defective molecular variants of glucose-6-phosphate dehydrogenase and methaemoglobin reductase, 134 Lesch-Nyhan syndrome, 55 Liver phosphorylase and related deficiency, 113 — diseases, inborn, 64 — system, role in mucopolysaccharidoses and mucolipidoses, 87 Malformations, congenital, 153 Mannosidosis, 84 Marcolly, bandicangued, prevalence of, inherited, metabolic disease		, asymmetrical, 125
—, chemistry of, 81 —, clinical and biological data in, 80 —, enzymology of, 81 —, pathology of, 80 Genetic control of protein synthesis, 1 — counselling and prenatal diagnosis, 150 — disease. See Inherited disease; Metabolic disease inherited — heterogeneity in glucose-6-phosphate dehydrogenase deficiency, 134 — in inherited disease, 32 Glucose-6-phosphate dehydrogenase, defective molecular variants of, 134, 135 — deficiency, future prospects for study of, 136 — heterogeneity of, 134 β-Glucuronidase deficiency, 74 Glutathione reductase activity, increase in, 54 Glycogen metabolism, disorders of, 108 — Martolly, bandicapned, prevalence of, inherited, metabolic disease. — Matter Martolly, bandicapned, prevalence of, inherited, metabolic disease.		
—, clinical and biological data in, 80 —, enzymology of, 81 —, pathology of, 80 Genetic control of protein synthesis, 1 — counselling and prenatal diagnosis, 150 — disease. See Inherited disease: Metabolic disease inherited — heterogeneity in glucose-6-phosphate dehydrogenase deficiency, 134 — in inherited disease, 32 Glucose-6-phosphate dehydrogenase, defective molecular variants of, 134, 135 — deficiency, future prospects for study of, 136 — — heterogeneity of, 134 β-Glucuronidase deficiency, 74 Glutathione reductase activity, increase in, 54 Glycogen metabolism, disorders of, 108 — due to multiple alleles, at single locus, 124 — gene loci, 125 — , secondary, 122 — , subunit structure of, 124 KAPLAN, J. C.: Defective molecular variants of glucose-6-phosphate dehydrogenase and methaemoglobin reductase, 134 Lesch-Nyhan syndrome, 55 Liver phosphorylase and related deficiencies, 116 Lysosomal 'acid maltase' deficiency, 113 — diseases, inborn, 64 — system, role in mucopolysaccharidoses and mucolipidoses, 87 Malformations, congenital, 153 Mannosidosis, 84 Marotelly, bandicapned, prevalence of inherited metabolic disease		
—, enzymology of, 81 —, pathology of, 80 Genetic control of protein synthesis, 1 — counselling and prenatal diagnosis, 150 — disease. See Inherited disease; Metabolic disease inherited — heterogeneity in glucose-6-phosphate dehydrogenase deficiency, 134 — in inherited disease, 32 Glucose-6-phosphates deficiency, 54, 112 Glucose-6-phosphates deficiency, 54, 112 Glucose-6-phosphate dehydrogenase, defective molecular variants of, 134, 135 — deficiency, future prospects for study of, 136 — heterogeneity of, 134 β-Glucuronidase deficiency, 74 Glutathione reductase activity, increase in, 54 Glycogen metabolism, disorders of, 108 — gene loci, 125 —, secondary, 122 KAPLAN, J. C.: Defective molecular variants of glucose-6-phosphate dehydrogenase and methaemoglobin reductase, 134 Lesch-Nyhan syndrome, 55 Liver phosphorylase and related deficiency, 113 — diseases, inborn, 64 — system, role in mucopolysaccharidoses and mucolipidoses, 87 Malformations, congenital, 153 Mannosidosis, 84 Marotelly, bandicapned, prevalence of inherited metabolic disease	, Chemistry Of, 81	
Genetic control of protein synthesis, 1 — counselling and prenatal diagnosis, 150 — disease. See Inherited disease; Metabolic disease inherited — heterogeneity in glucose-6-phosphate dehydrogenase deficiency, 134 — in inherited disease, 32 Glucose-6-phosphate deficiency, 54, 112 Glucose-6-phosphate dehydrogenase, defective molecular variants of, 134, 135 — deficiency, future prospects for study of, 136 — heterogeneity of, 134 β-Glucuronidase deficiency, 74 Glutathione reductase activity, increase in, 54 Glycogen metabolism, disorders of, 108 — subunit structure of, 124 KAPLAN, J. C.: Defective molecular variants of glucose-6-phosphate dehydrogenase and methaemoglobin reductase, 134 Lesch-Nyhan syndrome, 55 Liver phosphorylase and related deficiencies, 116 Lysosomal 'acid maltase' deficiency, 113 — diseases, inborn, 64 — system, role in mucopolysaccharidoses and mucolipidoses, 87 Malformations, congenital, 153 Mannosidosis, 84 Marctally, headicangued, prevalence of inherited metabolic disease	enzymology of 81	
Genetic control of protein synthesis, 1 — counselling and prenatal diagnosis, 150 — disease. See Inherited disease; Metabolic disease inherited — heterogeneity in glucose-6-phosphate dehydrogenase deficiency, 134 — in inherited disease, 32 Glucose-6-phosphate deficiency, 54, 112 Glucose-6-phosphate dehydrogenase, defective molecular variants of, 134, 135 — deficiency, future prospects for study of, 136 — heterogeneity of, 134 β-Glucuronidase deficiency, 74 Glutathione reductase activity, increase in, 54 Glycogen metabolism, disorders of, 108 — subunit structure of, 124 KAPLAN, J. C.: Defective molecular variants of glucose-6-phosphate dehydrogenase and methaemoglobin reductase, 134 Lesch-Nyhan syndrome, 55 Liver phosphorylase and related deficiencies, 116 Lysosomal 'acid maltase' deficiency, 113 — diseases, inborn, 64 — system, role in mucopolysaccharidoses and mucolipidoses, 87 Malformations, congenital, 153 Mannosidosis, 84 Marctally, headicangued, prevalence of inherited metabolic disease		
 counselling and prenatal diagnosis, 150 disease. See Inherited disease; Metabolic disease inherited heterogeneity in glucose-6-phosphate dehydrogenase deficiency, 134 in inherited disease, 32 Glucose-6-phosphatase deficiency, 54, 112 Glucose-6-phosphatase deficiency, 54, 112 Glucose-6-phosphate dehydrogenase, defective molecular variants of, 134, 135 — deficiency, future prospects for study of, 136 — heterogeneity of, 134 β-Glucuronidase deficiency, 74 Glutathione reductase activity, increase in, 54 Glycogen metabolism, disorders of, 108 Marotelly headicanged, prevalence of inherited metabolic disease. 	Genetic control of protein synthesis. 1	
— disease. See Inherited disease; Metabolic disease inherited — heterogeneity in glucose-6-phosphate dehydrogenase deficiency, 134 — in inherited disease, 32 Glucose-6-phosphatase deficiency, 54, 112 Glucose-6-phosphatase deficiency, 54, 112 Glucose-6-phosphatase deficiency, 54, 112 Glucose-6-phosphate dehydrogenase, defective molecular variants of, 134, 135 — deficiency, future prospects for study of, 136 — heterogeneity of, 134 B-Glucornidase deficiency, 74 Glutathione reductase activity, increase in, 54 Glycogen metabolism, disorders of, 108 Marotelly handicapped, prevalence of inherited metabolic disease.	— counselling and prenatal diagnosis, 150	, Subuliit Structure of, 124
— heterogeneity in glucose-6-phosphate dehydrogenase deficiency, 134 — in inherited disease, 32 Glucose-6-phosphatase deficiency, 54, 112 Glucose-6-phosphate dehydrogenase, defective molecular variants of, 134, 135 — deficiency, future prospects for study of, 136 — heterogeneity of, 134 β-Glucuronidase deficiency, 74 Glutathione reductase activity, increase in, 54 Glycogen metabolism, disorders of, 108 Mannosidosis, 84 Marcally, handing metabolic disease, 124 dehydrogenase and methaemoglobin reductase, 134 Lesch-Nyhan syndrome, 55 Liver phosphorylase and related deficiencies, 116 Lysosomal 'acid maltase' deficiency, 113 — diseases, inborn, 64 — system, role in mucopolysaccharidoses and mucolipidoses, 87 Malformations, congenital, 153 Mannosidosis, 84 Marcally, handing metabolic disease, 72	- disease. See Inherited disease; Metabolic disease inherited	KAPIAN, J. C.: Defective molecular variants of glucose-6-phosphate
134 — in inherited disease, 32 Glucose-6-phosphatase deficiency, 54, 112 Glucose-6-phosphate dehydrogenase, defective molecular variants of, 134, 135 — deficiency, future prospects for study of, 136 — heterogeneity of, 134 β-Glucuronidase deficiency, 74 Glutathione reductase activity, increase in, 54 Glycogen metabolism, disorders of, 108 Lesch-Nyhan syndrome, 55 Liver phosphorylase and related deficiencies, 116 Lysosomal 'acid maltase' deficiency, 113 — diseases, inborn, 64 — system, role in mucopolysaccharidoses and mucolipidoses, 87 Malformations, congenital, 153 Mannosidosis, 84 Marotelly, headicapped, prevalence of inherited metabolic disease.	- heterogeneity in glucose-6-phosphate dehydrogenase deficiency,	
Glucose-6-phosphatae deficiency, 54, 112 Glucose-6-phosphate dehydrogenase, defective molecular variants of, 134, 135 — deficiency, future prospects for study of, 136 — heterogeneity of, 134 β-Glucuronidase deficiency, 74 Glutathione reductase activity, increase in, 54 Glycogen metabolism, disorders of, 108 Glycogen metabolism, disorders of, 108 Liver phosphorylase and related deficiency, 113 — diseases, inborn, 64 — system, role in mucopolysaccharidoses and mucolipidoses, 87 Malformations, congenital, 153 Mannosidosis, 84 Marctally, bandicapped, prevalence of inherited metabolic disease.		,
Glucose-6-phosphate dehydrogenase, defective molecular variants of, 134, 135 — deficiency, future prospects for study of, 136 — heterogeneity of, 134 \$\beta\$-Glucuronidase deficiency, 74 Glutathione reductase activity, increase in, 54 Glycogen metabolism, disorders of, 108 Mannosidosis, 84 Marcully, bandicapped, prevalence of inherited metabolic disease.		
134, 135 — deficiency, future prospects for study of, 136 — heterogeneity of, 134 β-Glucuronidase deficiency, 74 Glutathione reductase activity, increase in, 54 Glycogen metabolism, disorders of, 108 Marotelly, bandicanged, prevalence of inherited metabolic disease.		
— deficiency, future prospects for study of, 136 — heterogeneity of, 134 β-Glucronidase deficiency, 74 Glutathione reductase activity, increase in, 54 Glycogen metabolism, disorders of, 108 Marotelly, bandicanced, prevalence, of inherited, metabolic disease.		
————, heterogeneity of, 134 \$\beta-Glucuronidase deficiency, 74 Glutathione reductase activity, increase in, 54 Glycogen metabolism, disorders of, 108 Malformations, congenital, 153 Mannosidosis, 84 Marcolaux-Lamy disease, 72		
B-Glucuronidase deficiency, 74 Glutathione reductase activity, increase in, 54 Glycogen metabolism, disorders of, 108 Maroteaux-Lamy disease, 72 Manually handicapped prevalence of inherited metabolic disease.		—— system, role in mucopolysaccharidoses and mucolipidoses, 87
Glutathione reductase activity, increase in, 54 Glycogen metabolism, disorders of, 108 Maroteaux-Lamy disease, 72		Malformations congenital 153
Glycogen metabolism, disorders of, 108 Maroteaux-Lamy disease, 72 Montally, handicapped, prevalence of inherited metabolic disease.		
Mentally handicanned prevalence of inherited metabolic disease		
	Aumo I 54 112	Mentally handicapped, prevalence of inherited metabolic disease
—		among, 158
 — — , — IV, 115 — — , — V, 116 — — , — , diagnostic service for, 160 — — , — , early detection (total population screening) in, 160 — — , types VII-IX, 117 Metabolic disease, inherited, coordination of services in, 162 — , — , diagnostic service for, 160 — , — , early detection (total population screening) in, 160 — , — , heterozygote detection in, 161 	, III, 114	
	, IV, 115	Metabolic disease, inherited, coordination of services in, 162
— — , — VI, 116 — — , —, early detection (total population screening) in, 160 — — , types VII-IX, 117 — — , —, heterozygote detection in, 161	, V, 116	———, ——, diagnostic service for, 160
, types VII-IX, 117, —, heterozygote detection in, 161	, VI, 116	———, ——, early detection (total population screening) in, 160
	, types VII-IX, 117	———, ——, neterozygote detection in, 161

Index

,, incidence based on paediatric admissions, 158	—— in red cell precursors, general pattern of, 2
———, ——, —————————————————————————————	—— in red cell precursors, general pattern of, 2 —— in red cells, 5
,, on probable proportion of mental sub-	Purine biosynthesis de novo, 48
normality patients, 158	— metabolism, molecular variation in relation to, 48
———, ——, of specific disorders, 156	ribonucleotide interconversion reactions, 51 salvage pathways, 50
,, information systems for, 159,, management of, ideal requirements for, 159	Pyruvate kinase deficiency, 128
	hiochemical effects of, 129
,, size of problem, 156	— — , biochemical effects of, 129 — — , clinical features of, 130 — , management of, 132
,, summary of size of problem, 158	, management of, 132
,, natural history of, 162	— in erythrocytes, 128
, , , , , , need for national policy for, 156 , , , , , size of problem, 156 , , , , , summary of size of problem, 158 , , , natural history of, 162 , , prenatal detection of, 162 , , prenatal detection of, 162	
,, prevalence among mentally handicapped, 158,, treatment of, 160	RAINE, D. N.: The need for a national policy for the management of
Metabolism, inborn errors of, 38-127	inherited metabolic disease, 156 Red cell(s). See Erythrocyte(s)
Methaemoglobin reductase, defective molecular variants of, 134, 138	Renal handling of uric acid, defects in, 59
————— deficiency, 137	Reticuloendothelial system, hyperplasia of, in β -thalassaemia major,
Methaemoglobinaemia, congenital, associated with neurological	17
involvement, 139	Ribonucleic acid, messenger, human, 3
MODELL, C. B.: The pathophysiology of β -thalassaemia major, 12	Ribonucleotide purine interconversion reactions, 51
Molecular variants, defective, of glucose-6-phosphate dehydrogenase,	RYMAN, B. E.: The glycogen storage diseases, 106
134, 135	SANDHOFF, K.: Sphingolipidoses, 94
——, —, of methaemoglobin reductase, 134, 138 —— variation in relation to purine metabolism, 48	Sanfilippo syndrome, 71
Morquio syndrome, 71	Scheie syndrome, 72
Mucolipidoses. See Mucopolysaccharidoses and mucolipidoses	Screening for sickle-cell disease, 28
Mucolipidosis, type I, 74	
—,— II, 75	Sickle-cell crisis, clinical management of, 23
	———, —— trials of prophylactic agents, 27
,, I-cells in, 75	———, established, clinical trials in, 27 ———, management of, 26
, ditrastructure of visceral tissues iii, 79	
Mucopolysaccharidoses and mucolipidoses, 64	, types of, 26, vaso-occlusive, and precipitating factors, 26
—————, chemical studies of, 64 ————, cultured fibroblast studies of, 66	—— disease, carrier state in, implications of, 29
, cultured fibroblast studies of, 66	, management of, 26
disorders related to, 86	, screening for, in community, 29
, enzymatic studies of, 65	,, in hospital patients and families, 28,, value and consequences of, 30
——————————————————————————————————————	Sickling process in relation to clinical manifestations, 23
, instorical and participant aspects of, or, lysosomal theory of, 64	SMITH, E. C. GORDON See GORDON-SMITH, E. C.
, role of lysosomal system in, 87	Sphingolipidoses, 94
, role of lysosomal system in, 87, ultrastructural studies of, 65	, catabolism of sphingolipids and enzyme deficiencies in, 96
Mucosulphatidosis, 84	, diagnosis and genetics in, 101
—, clinical and biological features of, 84	, different degrees of enzyme deficiencies in, 100
—, enzymology of, 85 —, pathological findings in, 85	—, nomenclature of, 94 —, role of isoenzymes in, 97
MUDD, S. H.: Vitamin-responsive genetic disease, 38	
Muscle phosphofructokinase deficiency, 117	—, therapeutic attempts in, 102 —, variant forms of, 96
—— phosphorylase deficiency, 116	Splenectomy in pyruvate kinase deficiency, 132
	STUART, J.: Management of sickle-cell disease, 26
Nucleic acid synthesis in red cell precursors, general pattern of, 2	Sulphydryl reactions and isozyme patterns, 123
	T 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Oxygen affinity changes in erythrocyte enzyme deficiencies, physio-	Tay-Sachs disease, screening for, 148 β-Thalassaemia major, pathophysiology of, 12
logical consequences of, 142	p-Thalassaemia major, pathophysiology of, 12
Discontinuosia commissa for 142	Uric acid, renal handling of, defects in, 59
Phenylketonuria, screening for, 142 Phosphofructokinase deficiency, muscle, 117	transport, 51
Phosphoribosylpyrophosphate amidotransferase, abnormality of, 55	Ween's and 10 d 11 th and 10
Phosphoribosylpyrophosphate-synthetase activity, increase in, 54	Vitamin coenzymes, defective binding to specific apoenzymes, 40 responsiveness, mechanisms of, 38
Phosphorylase deficiency, liver, 116	Vitamin-responsive genetic disease, 38
——, muscle, 116	Vitamins, defective metabolism of, 38
Danulatian annonina 145	, enhancement of alternative metabolic pathways by, 44
for galacteronemia 147	
- for cystic fibrosis, 148 - for galactosaemia, 147 - for histidinaemia, 146 - for phenylketonuria, 142 - for sickle-cell disease, 29	WATTS, R. W. E.: Molecular variation in relation to purine metabolism,
———— for phenylketonuria, 142	WEATHERALL, D. J.: The genetic control of protein synthesis: the
—— for sickle-cell disease, 29	haemoglobin model, 1
for Tay-Saciis disease, 146	WHITE, J. M.: The clinical features of unstable haemoglobin disease, 19
Prenatal diagnosis and genetic counselling, 150	
——, experience with, 152 ——, prospects and limitations, 154	Xanthine oxidase activity, increase in, 54
Protein synthesis, genetic, control of 1	Xanthinuria, 58 Xeroderma pigmentosum, 59
	pignivitosum, 57